<SEC-DOCUMENT>0001493152-21-024787.txt : 20211110
<SEC-HEADER>0001493152-21-024787.hdr.sgml : 20211110
<ACCEPTANCE-DATETIME>20211006161616
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-21-024787
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20211006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lucid Diagnostics Inc.
		CENTRAL INDEX KEY:			0001799011
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				825488042
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		ONE GRAND CENTRAL PLACE, SUITE 4600
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10165
		BUSINESS PHONE:		212 949 4319

	MAIL ADDRESS:	
		STREET 1:		ONE GRAND CENTRAL PLACE, SUITE 4600
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10165
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="formcorresp_001.jpg" ALT="" STYLE="height: 103px; width: 264px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FACSIMILE</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECT
    DIAL NUMBER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212)
818-8602</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eschwartz@graubard.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>***FOIA
Confidential Treatment Request***</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential
Treatment Requested by Lucid Diagnostics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>in
connection with its Registration Statement on Form S-1 (File No. 333-259721)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;October
6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lucid
    Diagnostics Inc. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    Statement on Form S-1 </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    September 22, 2021 </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
    No. 333-259721</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 55.1pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of our client, Lucid Diagnostics, Inc. (the &ldquo;<U>Company</U>&rdquo;), we hereby submit this letter to the staff (the &ldquo;<U>Staff</U>&rdquo;)
of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;). The purpose of this letter is to provide additional
information in connection with our response to comment number 8 from the Staff&rsquo;s letter dated August 6, 2021 (the &ldquo;<U>Comment
Letter</U>&rdquo;), relating to the above-referenced Registration Statement on Form S-1 (the &ldquo;<U>Registration Statement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 55.1pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 55.1pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the commercially sensitive nature of the information contained herein, this submission is accompanied by the Company&rsquo;s request
for confidential treatment of selected portions of this letter pursuant to Rule 83 of the Commission&rsquo;s Rules on Information and
Requests, 17 C.F.R. &sect;200.83. A redacted letter has been filed on EDGAR, omitting the confidential information contained in the letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 55.1pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 55.1pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the convenience of the Staff, we are providing to the Staff copies of this letter by electronic delivery. In this letter, we have recited
below the prior comment number 8 from the Staff, with the Company&rsquo;s response following immediately thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>8.</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
    note your response to comment 6 and that on page F-14 you have granted 1 million restricted shares during the three months ended
    March 31, 2021 and 65,000 restricted shares subsequent to March 31, 2021. Please provide an updated analysis between the recent valuations
    of your common stock leading up to the IPO and the estimated offering price that addresses the beneficial conversion feature of the
    notes, any stock options issued during six months prior to the offering and these restricted shares. This information will help facilitate
    our review of your accounting for equity issuances including stock compensation and beneficial conversion features.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant
to 17 C.F.R. &sect;200.83. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOIA
Confidential Treatment Request</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
To Rule 83 by Lucid Diagnostics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IPO
Price Range</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company advises the Staff that it currently anticipates that the price range for the initial public offering (&ldquo;<U>IPO</U>&rdquo;)
will be within the range of [***] to [***] per share (the &ldquo;<U>Preliminary Price Range</U>&rdquo;) with a mid-point price per share
of [***], before giving effect to a stock split that the Company plans to implement prior to effectiveness of the Registration Statement
(the &ldquo;<U>Stock Split</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual price range to be included in a subsequent amendment to the Registration Statement (which will comply with the Staff&rsquo;s interpretation
regarding the parameters of a <I>bona fide</I> price range) has not yet been determined and remains subject to adjustment based on factors
outside of the Company&rsquo;s control. However, the Company believes that the Preliminary Price Range set forth above will not be subject
to significant change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Historical
Fair Value Determination and Methodology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the above fair value determinations, for each grant date, the Board obtained and considered valuation reports prepared by a third-party
valuation firm in accordance with the guidance outlined in the American Institute of Certified Public Accountants Technical Practice
Aid, <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of the restricted stock awards granted under the 2018 Equity Plan, as discussed below, was determined using a probability-weighted
average expected return methodology (&ldquo;<U>PWERM</U>&rdquo;), which involves the determination of equity value under various exit
scenarios and an estimation of the return to the common stockholders under each scenario. In this regard, the Company common stock grant-date
estimated fair value was based upon an analysis of future values, assuming various outcomes, based upon the probability-weighted present
value of expected future investment returns, considering each of the possible future outcomes available to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PWERM principally involved (i) the identification of scenarios and related probabilities; (ii) determine the equity value under each
scenario; and (iii) determine the common stock shareholders&rsquo; return in each scenario. The two scenarios identified were an initial
public offering of the Company&rsquo;s common stock (&ldquo;<U>IPO scenario</U>&rdquo;) and continuing as a private company (&ldquo;<U>stay
private scenario</U>&rdquo;). With respect to the IPO scenario, the valuation of the Company&rsquo;s common stock was computed using
assumptions, including estimated dates of the initial public offering, to calculate an estimated pre-money valuation. With respect to
the stay private scenario, an income approach was used, wherein a risk-adjusted discount rate is applied to projected future cash flows.
A relative weighting of 75% was applied to the IPO scenario and 25% was assigned to the stay private scenario.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant
to 17 C.F.R. &sect;200.83. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOIA
Confidential Treatment Request</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
To Rule 83 by Lucid Diagnostics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Issuances</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2021, a total of 1,105,000 shares of restricted stock were granted under the Lucid Diagnostics Inc. 2018 Long-Term Incentive
Equity Plan (the &ldquo;<U>2018 Equity Plan</U>&rdquo;), with all of the restricted stock awards having been granted during the six months
ended June 30, 2021 and no other equity awards granted during such six-month period, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Grant
    Date</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares Underyling Restricted Stock Awards</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Estimated
    Fair Value Per Share For Financial Reporting Purposes</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">March 2021</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,040,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.20</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2021</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">65,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.50</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 1,040,000 restricted stock awards were granted under the 2018 Equity Plan in March 2021 to certain employees of PAVmed, to a
member of the board of directors of the Company (who is also a member of the board of directors of PAVmed), and to the three physician
inventors of the intellectual property licensed under the patent license agreement with Case Western Reserve University. The restricted
stock awards have a single vesting date of March 1, 2023, and an aggregate grant date fair value of approximately $18.9 million, determined
as discussed above. This reflects price per share of $18.20 determined by way of a 75% weight for an estimated IPO scenario price of
[***] per share and a weight of 25% for a stay private scenario price of [***] per share. The [***] per share estimated IPO scenario
price is [***] the estimated midpoint of the Preliminary Price Range. The aggregate estimated fair value is being recognized as stock-based
compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period, with the
full amount classified in general and administrative expense in the unaudited condensed statement of operations as of and for the six
months ended June 30, 2021. The restricted stock awards are subject to forfeiture if the requisite service period is not completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 65,000 restricted stock awards were granted under the 2018 Equity Plan in April 2021 to an employee of PAVmed Inc. and to a
member of the board of directors of the Company. The restricted stock awards have a single vesting date in April 2023, and an aggregate
grant date fair value of approximately $1.2 million, determined as discussed above. <FONT STYLE="background-color: white">This reflects
a price per share of $18.50 determined by way of a 75% weight for an estimated IPO scenario price of </FONT>[***] <FONT STYLE="background-color: white">per
share and a weight of 25% for a stay private scenario price of </FONT>[***] <FONT STYLE="background-color: white">per share. The </FONT>[***]
<FONT STYLE="background-color: white">per share estimated IPO scenario price is </FONT>[***] <FONT STYLE="background-color: white">the
estimated midpoint of the Preliminary Price Range. </FONT>The aggregate estimated fair value is being recognized as stock-based compensation
expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period, with approximately $1.1
million classified in general and administrative expense and $0.1 million classified in research and development expense in the unaudited
condensed statement of operations as of and for the six months ended June 30, 2021. The restricted stock awards are subject to forfeiture
if the requisite service period is not completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant
to 17 C.F.R. &sect;200.83. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOIA
Confidential Treatment Request</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
To Rule 83 by Lucid Diagnostics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restricted stock awards granted under the 2018 Equity Plan are discussed in further detail in the Company&rsquo;s unaudited condensed
financial statements as of and for the six months ended June 30, 2021 and 2020, in Note 9, <I>Stock-Based Compensation</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
to Preliminary Price Range</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the Preliminary Price Range, the midpoint of the price range for the IPO will exceed the fair values used for financial reporting
purposes in connection with the restricted stock awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
determination of the Preliminary Price Range was not based on a formal determination of fair value, but rather was based on discussions
between the Company and the representatives of the underwriters. In setting the Preliminary Price Range, the Company and the representatives
considered various factors, including, but not limited to, current securities market conditions, business, market and other developments
affecting the Company and the industry in which it participates, and the market for PAVmed&rsquo;s common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that the difference between the estimated fair value of its common stock for financial reporting purposes and the midpoint
of the Preliminary Price Range is the result of the following factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
    Market Conditions</I>. The expected offering price will take into consideration the valuation and performance of companies that the
    underwriters believe will be comparable to the Company, as well as the recent performance of successful initial public offerings
    outside of the Company&rsquo;s line of business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Probability
    of an IPO and Substantially Enhanced Liquidity and Marketability of the Company&rsquo;s Common Stock</I>. The prior valuations reflected
    the illiquidity of the Company&rsquo;s common stock at the time, as well as the uncertainty of an initial public offering. The expected
    offering price, on the other hand, represents the estimated fair value of freely tradable unrestricted common stock that will be
    sold in the public markets without discounts for illiquidity and lack of marketability. Notwithstanding the uncertainty of an initial
    public offering, in determining the fair value for financial reporting purposes, management employed a high probability (75%) for
    the IPO scenario, while using a low probability (25%) for the stay private scenario. Furthermore, the valuation used for the IPO
    scenario was [***] the midpoint of the Preliminary Price Range. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Enhanced
    Balance Sheet and Financial Resources</I>. The expected offering price assumes a successful offering which provides the Company with
    proceeds that (a) substantially strengthen the Company&rsquo;s balance sheet as a result of increased cash and access to public company
    debt and equity markets and (b) increase the probability that the Company will be successful in its product development initiatives.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant
to 17 C.F.R. &sect;200.83. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOIA
Confidential Treatment Request</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
To Rule 83 by Lucid Diagnostics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Product
    Development Milestones</I>. Upon acquiring the product license, the Company developed a strategic plan for regulatory approvals and
    commercial launch of initially laboratory developed test (LDT) and longer-term plan to receive PMA approval from the FDA for EsoGuard
    and EsoCheck as an IVD device via clinical trials. Since that time, the Company has advanced the strategic plan and has initiated
    the product launch, expanded the product pipeline, and commenced a clinical trial to pursue an FDA approval for a medical device.
    Many significant business milestones were achieved after the issuance of the restricted stock awards:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    May 2021, EsoCheck received CE Mark certification in Europe.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    July 2021, the Company entered into an agreement with UpScript, LLC to develop and operate a web-based platform for telemedicine
    consultations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    July 2021, the Company entered into an agreement to transfer the EsoCheck manufacturing to high-volume manufacturer Coastline International
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9675;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2021, the Company began testing patients referred by primary care physicians at three Lucid Test Centers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conclusion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the fair value for financial reporting purposes in connection with the restricted stock awards, management assumed a high
probability (75%) of an initial public offering and used an estimated price per share for the IPO scenario that was [***] the estimated
midpoint of the Preliminary Price Range. The price per share for the stay private scenario was determined using accepted valuation methodologies
and assumptions that were reasonable at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the above analysis, the Company respectfully submits to the Staff that the determination of the fair value of its common stock described
above was in accordance with ASC Topic 718 and consistent with the AICPA Practice Guide, and that the fair values used for financial
reporting purposes were reasonable and appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inapplicability
of Beneficial Conversion Feature Model</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in the Registration Statement and in our prior letter to the Staff dated September 3, 2021 (the &ldquo;<U>Prior Letter</U>&rdquo;),
the Company has issued to PAVmed Inc. (&ldquo;<U>PAVmed</U>&rdquo;), its parent, a Senior Unsecured Promissory Note, dated June 1, 2021,
with a face value principal of $22.4 million, an annual interest rate of 7.875%, and a maturity date of May 18, 2028 (the &ldquo;<U>Convertible
Note</U>&rdquo;). The Convertible Note replaced the $22.4 million aggregate amount of the &ldquo;Due To: PAVmed Inc.&rdquo; payment obligations
outstanding and payable as of June 1, 2021. The Convertible Note provides for the partial or full repayment of the face value principal
and accrued but not paid interest thereon by the issue of shares of the Company&rsquo;s common stock, at a conversion price of $2.00
per share, with such conversion at the election of PAVmed. It is expected PAVmed will convert the principal and unpaid interest expense
into shares of the Company&rsquo;s common stock prior to the consummation of the IPO. As discussed in the Prior Letter, the Company believes
the conversion price is materially consistent with the fair value of the Company&rsquo;s common stock in light of the overall timing
of the advances and other payments by PAVmed and the actions by the Company&rsquo;s board of directors with respect to establishing the
conversion price and issuing the Convertible Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant
to 17 C.F.R. &sect;200.83. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOIA
Confidential Treatment Request</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
To Rule 83 by Lucid Diagnostics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
the Company respectfully submits that an evaluation of the conversion price of the Convertible Note as a beneficial conversion feature
(&ldquo;<U>BCF</U>&rdquo;) was not required, and accordingly no determination of the fair value of the Company&rsquo;s common stock was
made, in connection with the accounting for the Convertible Note. As mentioned above, the Convertible Note ultimately was dated June
1, 2021, and, as such, an evaluation of its conversion price as a BCF was not required as a result of the elimination of the &ldquo;BCF
Model/Construct&rdquo; from the Financial Accounting Standards Board (&ldquo;<U>FASB</U>&rdquo;) Accounting Standards Codification Topic
470, <I>Debt</I>, as a result of the promulgation by the FASB in August 2020 of its Accounting Standards update (&ldquo;<U>ASU</U>&rdquo;)
2020-06. In this regard, ASU 2020-06 was adopted by the Company on January 1, 2021, as discussed in the Company&rsquo;s financial statements
as of and for the years ended December 31, 2020 and 2019, in Note 2, <I>Summary of Significant Accounting Policies and Recent Accounting
Standards Updates - Recent Accounting Standards Updates</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
there was no fair value determination in connection with the accounting for the Convertible Note, the Company&rsquo;s respectfully submits
that comparison to the Preliminary Price Range is not necessary or possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * * * *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If you have any questions or need any further information, please do not hesitate to contact me at the telephone number or
electronic mail address set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Eric T. Schwartz</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    T. Schwartz</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lishan
    Aklog, M.D.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 55.1pt; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant
to 17 C.F.R. &sect;200.83. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 55.1pt; background-color: white"></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 55.1pt; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formcorresp_001.jpg
<TEXT>
begin 644 formcorresp_001.jpg
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M^01>?]<7_E7"?!?GPQ=#&?\ 26XK1L?AIIUEXVFUY0"C?,D..%?N:Q/B^?\
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M"+C)J=D5U*L 5(P0>]4ET335MGMUL8!#(=S1A!AC[BK<4,<$2QPHJ1J,*JC
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MBEA:31A9XPT10[E(/.?\:?XPTN[U/5]&6SDE@ECRRRH.%;MGVJ#0(=9GL_$
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4***********************__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
